Search
Asparagine
go.drugbank.com/drugs/DB00174ApprovedNutraceuticalWithdrawnA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and M...
Neltenexine
go.drugbank.com/drugs/DB13239InvestigationalNeltenexine is an elastase inhibitor. It may be useful for preventing pulmonary emphysema.
VX-148
go.drugbank.com/drugs/DB06103ExperimentalVX-148 is a developed for the treatment of autoimmune diseases.
Danazol
go.drugbank.com/drugs/DB01406ApprovedInvestigationalA synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsPegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalFood and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients with phenylketonuria (PKU). … [L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigationalNaxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside. … [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015.
ATB-346
go.drugbank.com/drugs/DB15377InvestigationalATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
Guanadrel
go.drugbank.com/drugs/DB00226ApprovedGuanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
ETC-588
go.drugbank.com/drugs/DB05456ExperimentalIt is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis. … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes.
Butorphanol
go.drugbank.com/drugs/DB00611ApprovedIllicitVet approvedA synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.